Form 4: Pulse Biosciences Director Richard van den Broek Acquires Stock Options

Director Richard van den Broek of Pulse Biosciences, Inc. acquired stock options on June 6, 2024.

Summary

• Richard van den Broek, a director at Pulse Biosciences, Inc., acquired stock options on June 6, 2024.
• He obtained options to purchase 20,000 shares and 11,649 shares of common stock at an exercise price of $14.55.
• The first set of options (20,000 shares) will vest in equal monthly installments over one year, starting July 6, 2024.
• The second set of options (11,649 shares) will vest in equal quarterly installments over one year, starting September 5, 2024.
• Vesting is contingent upon van den Broek's continued service with the company.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing. The sentiment is neutral as it simply reports the acquisition of stock options by a company director.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. These filings provide transparency into insider transactions and are closely watched by investors.

Stakeholder Impact

• The acquisition of stock options by a director could potentially increase shareholder confidence.

Key Dates